Esophageal Cancer Clinical Trial
Official title:
Effectiveness of a Rehabilitation Program in Improving Sleep Quality, Emotional Distress, Circadian Rhythms, and Quality of Life in Patients With Esophageal Cancer
Verified date | May 2023 |
Source | Taipei Veterans General Hospital, Taiwan |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study will investigate the effectiveness of a rehabilitation program in improving sleep quality, emotional distress, circadian rhythms, and quality of life in patients with esophageal cancer in Taiwan. Hypothesis: 1. The quality of life in exercise group is significant improving than usual-care group at 3rd, 6th, 12th, 24th, and 36th month. 2. The quality of sleep in exercise group is significant improving than usual-care group at 3rd, 6th, 12th, 24th, and 36th month. 3. The emotional distress in exercise group is significant improving than usual-care group at 3rd, 6th, 12th, 24th, and 36th month. 4. The circadian rhythms in exercise group is significant improving than usual-care group at 3rd, 6th, 12th, 24th, and 36th month.
Status | Active, not recruiting |
Enrollment | 85 |
Est. completion date | July 2024 |
Est. primary completion date | July 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 20 Years and older |
Eligibility | Inclusion Criteria: - Patients with esophageal cancer who were aged =20 years, could communicate in either Mandarin or Taiwanese, and were not cognitively impaired were included. Exclusion Criteria: - |
Country | Name | City | State |
---|---|---|---|
Taiwan | National Taipei University of Nursing and Health Sciences | Taipei |
Lead Sponsor | Collaborator |
---|---|
Taipei Veterans General Hospital, Taiwan |
Taiwan,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Quality of life (EORTC QLQ-C30 ) | using European Organization for Research and Treatment cancer QLQ-C30 (EORTC) to measure quality of life. | baseline | |
Primary | Quality of life (EORTC QLQ-C30 ) | using European Organization for Research and Treatment cancer QLQ-C30 (EORTC) to measure quality of life. | 3rd month after recruited | |
Primary | Quality of life (EORTC QLQ-C30 ) | using European Organization for Research and Treatment cancer QLQ-C30 (EORTC) to measure quality of life. | 6th month after recruited | |
Primary | Quality of life (EORTC QLQ-C30 ) | using European Organization for Research and Treatment cancer QLQ-C30 (EORTC) to measure quality of life. | 12th month after recruited | |
Primary | Quality of life (EORTC QLQ-C30 ) | using European Organization for Research and Treatment cancer QLQ-C30 (EORTC) to measure quality of life. | 24th month after recruited | |
Primary | Quality of life (EORTC QLQ-C30 ) | using European Organization for Research and Treatment cancer QLQ-C30 (EORTC) to measure quality of life. | 36th month after recruited | |
Primary | Quality of life (EORTC QLQ-OES 18 ) | using European Organization for Research and Treatment cancer QLQ-OES 18 (EORTC) to measure quality of life. | baseline | |
Primary | Quality of life (EORTC QLQ-OES 18 ) | using European Organization for Research and Treatment cancer QLQ-OES 18 (EORTC) to measure quality of life. | 3rd month after recruited | |
Primary | Quality of life (EORTC QLQ-OES 18 ) | using European Organization for Research and Treatment cancer QLQ-OES 18 (EORTC) to measure quality of life. | 6th month after recruited | |
Primary | Quality of life (EORTC QLQ-OES 18 ) | using European Organization for Research and Treatment cancer QLQ-OES 18 (EORTC) to measure quality of life. | 12th month after recruited | |
Primary | Quality of life (EORTC QLQ-OES 18 ) | using European Organization for Research and Treatment cancer QLQ-OES 18 (EORTC) to measure quality of life. | 24th month after recruited | |
Primary | Quality of life (EORTC QLQ-OES 18 ) | using European Organization for Research and Treatment cancer QLQ-OES 18 (EORTC) to measure quality of life. | 36th month after recruited | |
Secondary | Subjective sleep quality | using Pittsburgh Sleep Quality Index | baseline | |
Secondary | Subjective sleep quality | using Pittsburgh Sleep Quality Index | 3rd month after recruited | |
Secondary | Subjective sleep quality | using Pittsburgh Sleep Quality Index | 6th month after recruited | |
Secondary | Subjective sleep quality | using Pittsburgh Sleep Quality Index | 12th month after recruited | |
Secondary | Subjective sleep quality | using Pittsburgh Sleep Quality Index | 24th month after recruited | |
Secondary | Subjective sleep quality | using Pittsburgh Sleep Quality Index | 36th month after recruited | |
Secondary | Objective sleep quality | using Actigraph for measure Objective sleep quality | baseline | |
Secondary | Objective sleep quality | using Actigraph for measure Objective sleep quality | 3rd month after recruited | |
Secondary | Objective sleep quality | using Actigraph for measure Objective sleep quality | 6th month after recruited | |
Secondary | Objective sleep quality | using Actigraph for measure Objective sleep quality | 12th month after recruited | |
Secondary | Objective sleep quality | using Actigraph for measure Objective sleep quality | 24th month after recruited | |
Secondary | Objective sleep quality | using Actigraph for measure Objective sleep quality | 36th month after recruited | |
Secondary | Emotional distress | Emotional distress including anxiety and depression (Hospital Anxiety and Depression Scale). The Hospital Anxiety and Depression Scale include anxiety and depression subscales, a total of 7 questions, each subscale is a four-point scoring method, 0 point for "not at all", 3 points for "always do", each subscale scores is between 0 and 21, that a score of 7 or less for non-cases, scores of 8-10 for doubtful cases and scores of 11 or more for definite cases. | baseline, 3rd month, 6th month, 12th month, 24th month, and 36th month after recruited | |
Secondary | Circadian rhythms | Circadian rhythms including 24-h autocorrelation coefficient (r24) and in bed less than out of bed dichotomy index (Ibaseline, 3rd month, 6th month, 12th month, 24th month, and 36th month after recruited |
| |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Terminated |
NCT01624090 -
Mithramycin for Lung, Esophagus, and Other Chest Cancers
|
Phase 2 | |
Recruiting |
NCT05787522 -
Efficacy and Safety of AI-assisted Radiotherapy Contouring Software for Thoracic Organs at Risk
|
||
Not yet recruiting |
NCT05542680 -
Study on the Design and Application of Special Semi Recumbent Cushion for Postoperative Patients With Esophageal Cancer
|
N/A | |
Completed |
NCT03384511 -
The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.
|
Phase 4 | |
Completed |
NCT00003864 -
Docetaxel Plus Carboplatin in Treating Patients With Advanced Cancer of the Esophagus
|
Phase 2 | |
Recruiting |
NCT05491616 -
Nivolumab During Active Surveillance After Neoadjuvant Chemoradiation for Esophageal Cancer: SANO-3 Study
|
Phase 2 | |
Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
Completed |
NCT00199849 -
NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine
|
Phase 1 | |
Completed |
NCT03756597 -
PAN-study: Pan-Cancer Early Detection Study (PAN)
|
||
Completed |
NCT00400114 -
Sutent Following Chemotherapy, Radiation and Surgery For Resectable Esophageal Cancer
|
Phase 2 | |
Completed |
NCT03652077 -
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies
|
Phase 1 | |
Recruiting |
NCT04615806 -
The Value of Lymph Node Dissection of Indocyanine Green-guided Near-infrared Fluorescent Imaging in Esophagectomy
|
N/A | |
Active, not recruiting |
NCT04566367 -
Blue Laser Imaging (BLI) for Detection of Secondary Head and Neck Cancer
|
N/A | |
Active, not recruiting |
NCT03962179 -
Feasibility and Efficacy of a Combination of a SEMS and Vacuum Wound Treatment (VACStent)
|
N/A | |
Terminated |
NCT01446874 -
Prevention of Post-operative Pneumonia (POPP)
|
Phase 2/Phase 3 | |
Completed |
NCT03468634 -
Raman Probe for In-vivo Diagnostics (During Oesophageal) Endoscopy
|
N/A | |
Active, not recruiting |
NCT02869217 -
Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors
|
Phase 1 | |
Completed |
NCT02810652 -
Perioperative Geriatrics Intervention for Older Cancer Patients Undergoing Surgical Resection
|
N/A | |
Recruiting |
NCT01404156 -
Preoperative Chemotherapy vs. Chemoradiation in Esophageal / GEJ Adenocarcinoma
|
Phase 2/Phase 3 |